近日，深圳迈瑞医疗正式取得深圳惠泰医疗的控制权，本次交易对价约为66.5亿元人民币。方达律师事务所担任收购方迈瑞医疗的交易法律顾问，嘉源律师事务所则为转让方提供法律服务。
据悉，本次交易是中国A股资本市场科创板首单“现金A收A”实现控制权转让的交易，同时也是中国境内医疗器械企业之间迄今交易金额最高的并购交易。
惠泰医疗成立于2002年，是一家专注于心脏电生理和介入医疗器械研发、生产和销售的高新技术企业，2021年1月于科创板上市。
迈瑞医疗创始于1991年，是全球创新的医疗器械与解决方案供应商，在全球超过30个国家设有44家境外子公司。
方达大湾区深圳办公室、香港办公室，以及上海办公室共同提供服务。团队由公司组合伙人楼伟亮及合伙人马强牵头共同领导；反垄断组合伙人韩亮及合伙人王瑾就并购涉及的经营者集中申报事宜向客户提供了法律建议；基金组合伙人唐婕人就基金监管事宜向客户提供了法律建议；合伙人傅钟琦及合伙人冯璐就交易合规事宜向客户提供了法律建议。
嘉源团队主要成员包括高级合伙人王元律师、张璇律师。
近日，德国汉高完成收购宝洁公司旗下沙宣品牌的大中华区业务。方达律师事务所、美国佳利律师事务所为收购方汉高提供了法律服务。
本次交易对价未公开，但根据此前数据，沙宣大中华区业务在2022-2023财年实现超过2亿欧元的销售额。
沙宣产品组合由宝洁公司于1997年正式引入中国市场，至今已在中国市场深耕27年。总部位于德国的汉高是工业和消费品领域的全球领导者。沙宣的加入补充了汉高消费品牌在中国本土市场的业务组合，填补了高端零售市场的空白。
方达北京办公室、上海办公室以及香港办公室在本次交易中紧密合作，项目由反垄断组合伙人韩亮、黄菁，公司组合伙人李祥、许馨月和陈伟祈，以及银行组合伙人汪麒牵头。
佳利团队由纽约办公室合伙人Glenn McGrory领导，同时得到北京办公室合伙人萧婉婷协助。
Fangda, Jia Yuan, Cleary on APT Medical, Sassoon’s M&A deals
Shenzhen-based medical equipment manufacturer Mindray has officially acquired control of Shenzhen APT Medical, with the transaction valued at approximately $ 9.19 million. Fangda Partners served as the legal advisor for the acquirer, Mindray, while Jia Yuan Law Offices provided legal services to the seller.
This transaction is noted as the first control transfer deal in cash on China's A-share capital market's STAR Market, and it is also the highest transaction amount to date among domestic medical device companies in China.
Established in 2002, APT Medical is a high-tech enterprise specializing in the R&D, production, and sales of cardiac electrophysiology and interventional medical devices, and it was listed on the STAR Market in January 2021.
Founded in 1991, Mindray is a global innovator in medical devices and solutions, with 44 subsidiaries across more than 30 countries worldwide.
The Fangda team was jointly led by corporate partners Leo Lou and Ma Qiang, with antitrust partners Michael Han and Wang Jin providing legal advice on merger filings; funds partner Candy Tang on regulatory matters; and partners Allen Fu and Sophia Feng on transaction compliance.
The Jia Yuan team included senior partners Wang Yuan and Zhang Xuan.
Germany's Henkel has recently completed the acquisition of the Greater China business of Procter & Gamble's Vidal Sassoon brand. Fangda Partners and the U.S. law firm Cleary Gottlieb provided legal services for the acquirer.
The transaction value was not disclosed, but based on previous data, Vidal Sassoon's Greater China operations generated over 200 million euros in sales during the 2022-2023 fiscal year.
Introduced into the Chinese market by Procter & Gamble in 1997, Vidal Sassoon has been deeply entrenched in the Chinese market for 27 years. Headquartered in Germany, Henkel is a global leader in the industrial and consumer goods sectors. The addition of Vidal Sassoon enhances Henkel's portfolio of consumer brands in the Chinese domestic market, filling a gap in the high-end retail market.
The Fangda team in Beijing, Shanghai, and Hong Kong offices closely cooperated in this transaction, led by antitrust partners Michael Han and Caroline Huang, corporate partners Patrick Li, Sherry Xu, and Raymond Chan, and banking partner Rock Wang.
The Cleary team was led by New York partner Glenn McGrory, assisted by Beijing partner Denise Shiu.
